An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
Thomas O’Connor
Advertisement
Thomas O’Connor is chemical engineer, science staff at the Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, FDA.
Articles by Thomas O’Connor
In-silico design facilitates process optimization and evaluation of process control strategies.
Advertisement
Latest Updated Articles
Flowsheet Models Modernize Pharmaceutical Manufacturing Design and Risk AssessmentPublished: April 2nd 2015 | Updated:
Regulatory Considerations for Controlled Correspondence Related to Generic Drug ChemistryPublished: September 1st 2015 | Updated:
Advertisement
Advertisement
